CN102421436B - 别嘌呤醇在制备用于治疗手足皮肤反应的药物中的用途 - Google Patents

别嘌呤醇在制备用于治疗手足皮肤反应的药物中的用途 Download PDF

Info

Publication number
CN102421436B
CN102421436B CN201080019054.2A CN201080019054A CN102421436B CN 102421436 B CN102421436 B CN 102421436B CN 201080019054 A CN201080019054 A CN 201080019054A CN 102421436 B CN102421436 B CN 102421436B
Authority
CN
China
Prior art keywords
allopurinol
treatment
hfsr
medicine
hand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080019054.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102421436A (zh
Inventor
亚兰达·罗德莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advancell Advanced In Vitro Cell Technologies SA
Nobera Pharma SL
Original Assignee
Advancell Advanced In Vitro Cell Technologies SA
Nobera Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancell Advanced In Vitro Cell Technologies SA, Nobera Pharma SL filed Critical Advancell Advanced In Vitro Cell Technologies SA
Publication of CN102421436A publication Critical patent/CN102421436A/zh
Application granted granted Critical
Publication of CN102421436B publication Critical patent/CN102421436B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080019054.2A 2009-04-29 2010-04-29 别嘌呤醇在制备用于治疗手足皮肤反应的药物中的用途 Expired - Fee Related CN102421436B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
US61/214,894 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
EP09382058.7 2009-04-29
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (2)

Publication Number Publication Date
CN102421436A CN102421436A (zh) 2012-04-18
CN102421436B true CN102421436B (zh) 2014-05-07

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080019054.2A Expired - Fee Related CN102421436B (zh) 2009-04-29 2010-04-29 别嘌呤醇在制备用于治疗手足皮肤反应的药物中的用途

Country Status (22)

Country Link
US (2) US8623878B2 (enExample)
EP (2) EP2246057A1 (enExample)
JP (1) JP6007101B2 (enExample)
KR (1) KR20120049848A (enExample)
CN (1) CN102421436B (enExample)
AR (1) AR076505A1 (enExample)
AU (2) AU2010243594A1 (enExample)
BR (1) BRPI1011971A2 (enExample)
CA (1) CA2759085C (enExample)
DK (1) DK2424538T3 (enExample)
ES (1) ES2434366T3 (enExample)
HR (1) HRP20131070T1 (enExample)
IL (1) IL215831A (enExample)
ME (1) ME01567B (enExample)
MX (1) MX2011011529A (enExample)
NZ (1) NZ595901A (enExample)
PL (1) PL2424538T3 (enExample)
PT (1) PT2424538E (enExample)
RS (1) RS53005B (enExample)
RU (1) RU2543325C2 (enExample)
SI (1) SI2424538T1 (enExample)
WO (1) WO2010125143A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987336B2 (en) 2018-04-16 2021-04-27 Onquality Pharmaceuticals China Ltd. Method of preventing or treating side effect of tumor therapy

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010306671B2 (en) 2009-10-16 2015-12-17 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
CA3085013A1 (en) 2017-12-13 2019-06-20 Onquality Pharmaceuticals China Ltd. A method for preventing or treating egfr-inhibition associated diseases
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US20250114362A1 (en) 2022-01-05 2025-04-10 Asymmetric Therapeutics, Llc Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138103A1 (en) * 2006-06-01 2007-12-06 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3772193D1 (de) * 1987-02-13 1991-09-19 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JP4822652B2 (ja) * 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
US20030157191A1 (en) * 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2004110380A2 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148907A1 (en) * 2003-12-24 2005-07-07 Gregory Skover Treatment of skin using a benefit agent and an apparatus
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
ES2312012T3 (es) 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138103A1 (en) * 2006-06-01 2007-12-06 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dermatologic symptoms associated with the multikinase inhibitor sorafenib;ROBERT C. et al;《J, AM. ACAD. Dermatol.》;20090201;第60卷(第2期);299-305 *
Dernatological reactions to the multitargeted syrosine kinase inhibitor sunitinib;ROSENBAUM S E et al;《Support Care Cancer》;20080215;第16卷(第6期);557-566 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987336B2 (en) 2018-04-16 2021-04-27 Onquality Pharmaceuticals China Ltd. Method of preventing or treating side effect of tumor therapy

Also Published As

Publication number Publication date
US20100280051A1 (en) 2010-11-04
RS53005B (sr) 2014-04-30
US20140080845A1 (en) 2014-03-20
PL2424538T3 (pl) 2014-05-30
DK2424538T3 (da) 2013-11-04
KR20120049848A (ko) 2012-05-17
IL215831A0 (en) 2012-01-31
CA2759085C (en) 2016-08-16
EP2246057A1 (en) 2010-11-03
RU2543325C2 (ru) 2015-02-27
ES2434366T3 (es) 2013-12-16
PT2424538E (pt) 2013-11-07
RU2011148355A (ru) 2013-06-10
NZ595901A (en) 2013-11-29
ME01567B (me) 2014-04-20
EP2424538B1 (en) 2013-08-14
US8623878B2 (en) 2014-01-07
WO2010125143A1 (en) 2010-11-04
CA2759085A1 (en) 2010-11-04
AU2016228193A1 (en) 2016-11-03
JP6007101B2 (ja) 2016-10-12
HK1168042A1 (en) 2012-12-21
MX2011011529A (es) 2012-02-08
SI2424538T1 (sl) 2013-12-31
BRPI1011971A2 (pt) 2016-04-26
IL215831A (en) 2016-02-29
CN102421436A (zh) 2012-04-18
HRP20131070T1 (hr) 2013-12-20
EP2424538A1 (en) 2012-03-07
AR076505A1 (es) 2011-06-15
AU2010243594A1 (en) 2011-11-10
JP2012525358A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
JP5028480B2 (ja) 手足症候群の治療のためのアロプリノールの使用
AU2016228193A1 (en) Use of allopurinol for the treatment of hand foot skin reaction
CN101460172B (zh) 别嘌醇在制备治疗手足综合征的药物中的用途
HK1168042B (en) Use of allopurinol for the treatment of hand foot skin reaction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140507

Termination date: 20170429